| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Repligen Corporation |
| Information provided by: | Repligen Corporation |
| ClinicalTrials.gov Identifier: | NCT00036231 |
Purpose
The purpose of the study is to determine the effect of multiple doses of secretin on autism.
| Condition | Intervention | Phase |
|
Autism |
Drug: RG1068 (Synthetic Human Secretin) |
Phase III |
| MedlinePlus related topics: | Autism |
| Drug Information available for: | Secretin Human secretin |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study |
| Official Title: | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Efficacy, Safety and Tolerability of RG1068 (Synthetic Human Secretin) in Children With Autism and Gastrointestinal Dysfunction |
Eligibility
| Ages Eligible for Study: | 32 Months to 59 Months |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Contacts and Locations More Information
Related Info
|
| Study ID Numbers: | RG1068-03 |
| First Received: | May 8, 2002 |
| Last Updated: | November 17, 2005 |
| ClinicalTrials.gov Identifier: | NCT00036231 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|
